

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M. 10247 - CVC/Cooper

SECTION 1.2

Description of the concentration

On 17 September 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) 139/2004 involving the acquisition of sole control of Alpha TopCo S.A.S. (the "**Target**") by CVC Capital Partners SICAV-FIS S.A. ("**CVC**") within the meaning of Article 3(1)(b) of Council Regulation (EC) No 139/2004.

The primary business activities of the undertakings are

(a) For CVC, CVC and/or its subsidiaries manage investment funds and platforms. CVC Funds' Portfolio Companies in the pharmaceutical sector include:

- (i) **Genetic** – an integrated pharmaceutical company focused on the research, development, manufacturing, licensing and promotion of pharmaceutical specialties and medical devices;
- (ii) **Theramex** – a global specialty pharmaceutical company dedicated to women's health products; and
- (iii) **Recordati** – a pharmaceutical company producing pharmaceuticals, both generic and under licence, including drugs for the treatment of hypertension and other cardiovascular disorders, disorders of the lower urinary tract as well as drugs for the treatment of rare diseases.

(b) The Target produces and markets, through Cooper Consumer Health S.A.S. and its subsidiaries, various self-care products used for diagnosis, prevention, treatment and enhancements.